KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology,Hematology
Reference31 articles.
1. Multiple Myeloma;Palumbo;New England Journal of Medicine,2011
2. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients;Kumar;Leukemia,2014
3. Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making;Clark;Am J Hematol,2016
4. Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity;Cornell;Bone Marrow Transplant,2016
5. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy;Gandhi;Leukemia,2019
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Retrospective study on pomalidomide‐PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma;European Journal of Haematology;2024-06-19
2. Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias;Leukemia & Lymphoma;2024-06-02
3. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy;Transplantation and Cellular Therapy;2024-01
4. Real-world clinical outcomes in patients with relapsed and refractory multiple myeloma receiving VTD-PACE treatment in the era of monoclonal antibodies;Annals of Hematology;2023-09-05
5. Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in Myeloma;Transplantation and Cellular Therapy;2023-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3